Chronic Hepatitis B
May 12, 2026
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China; Artiva Announces Strong Early AlloNK® Results and FDA Alignment for Pivotal Rheumatoid Arthritis Trial in 2026; FDA Reviews LEQEMBI IQLIK Subcutaneous Starting Dose Under Priority Review Pathway; ParcelBio Announces Programmable mRNA Platform Amid $13M Capital Infusion; Entrada Therapeutics Reports Promising Topline Efficacy and Safety Results for ENTR-601-44 in Duchenne Muscular Dystrophy
GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China GSK plc revealed an exclusive strategic partnership with Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aimed at supporting the launch and expansion of bepir...
Read More...
May 05, 2026
UCB to Acquire Candid Therapeutics; Pfizer’s ELREXFIO Sets New Benchmark in PFS for Hard-to-Treat Multiple Myeloma Patients; Axsome Therapeutics Wins FDA Approval for AUVELITY to Address Alzheimer’s Agitation; FDA Advisory Panel Backs Truqap for PTEN-Deficient mHSPC; Bepirovirsen Receives FDA Priority Review Alongside Breakthrough Therapy Tag
UCB Bets on Candid Therapeutics to Boost Immunology Pipeline with T-cell Engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics, strengthening its immunology pipeline and advancing its capabilities in next-generation biologics, particularly T-cell engagers (TCEs). The deal aligns wit...
Read More...
Jan 12, 2026
Chronic Hepatitis B: The Silent Epidemic Hiding in Plain Sight
Summary Chronic hepatitis B continues to pose a major global health challenge, affecting millions globally. ~5 million prevalent CHB cases across the 7MM in 2024. No complete cure exists yet, but advances in antivirals and novel modalities are reshaping therapeutic outcomes and hope for a functional cure. ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
